A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genetic analysis company BGI Genomics after finding that Illumina's DNA-sequencing systems infringed two patents.
BGI and Illumina have been embroiled in a global legal battle over their respective sequencing technologies.